{"schema_version":"1.0","type":"article","title":"Zolgensma tumors put Novartis's older-patient SMA growth at risk","url":"https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients-en.md","lang":"en","date":"2026-11-11","publish_at":"2026-11-11T08:00:00+08:00","updated_at":"2026-11-11","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["Novartis","Zolgensma","Gene therapy","SMA","Itvisma"],"summary":"Novartis confirmed nine tumor reports after Zolgensma, two with vector DNA near the GLI1 oncogene; the FDA reportedly extends the risk to Itvisma. Infant use stays; the older-patient market gets repriced.","key_points":["The infant product stays with added monitoring, while Itvisma's older-patient market gets repriced.","Novartis confirmed nine tumor reports on November 5, two with vector DNA integrated near GLI1.","Zolgensma group sales rose 34% to $404 million in Q3 2026, with US growth driven by Itvisma."],"facts":[{"claim":"Zolgensma 上市以來腫瘤通報數","value":9,"unit":"例","as_of":"2026-11-05","source":"BioSpace 2026-11-05"},{"claim":"腫瘤組織找到載體整合的個案","value":2,"unit":"例","as_of":"2026-11-06","source":"swissinfo 2026-11-06"},{"claim":"做過詳細組織分析的個案","value":3,"unit":"例","as_of":"2026-11-06","source":"swissinfo 2026-11-06"},{"claim":"全球累計治療人數","value":">6000","unit":"人","as_of":"2026-11-05","source":"BioSpace 2026-11-05"},{"claim":"與 GLI1 相關的腫瘤個案","value":3,"unit":"例","as_of":"2026-11-06","source":"Newsroom America 2026-11-06"},{"claim":"Zolgensma 產品群 Q3 營收","value":404,"unit":"百萬美元","as_of":"2026-09-30","source":"Novartis Q3 2026 interim report"},{"claim":"Zolgensma 產品群 Q3 年增率","value":34,"unit":"%","as_of":"2026-09-30","source":"Novartis Q3 2026 interim report"},{"claim":"Zolgensma 產品群 Q3 美國營收","value":173,"unit":"百萬美元","as_of":"2026-09-30","source":"Novartis Q3 2026 interim report"},{"claim":"美國 Q3 年增率","value":78,"unit":"%","as_of":"2026-09-30","source":"Novartis Q3 2026 interim report"},{"claim":"Itvisma FDA 核准日","value":"2025-11-24","unit":"日期","as_of":"2025-11-24","source":"NeurologyLive 2025-11-24"},{"claim":"STEER 試驗人數","value":126,"unit":"人","as_of":"2025-11-24","source":"NeurologyLive 2025-11-24"},{"claim":"STEER 52 週 HFMSE 改善（Itvisma／假注射）","value":"2.39/0.51","unit":"分","as_of":"2025-11-24","source":"NeurologyLive 2025-11-24"},{"claim":"Skysona 試驗血液惡性腫瘤比例","value":15,"unit":"%","as_of":"2025-08-11","source":"pharmaphorum 2025-08-11"},{"claim":"Elevidys 黑框警語時間","value":"2025-11","unit":"年月","as_of":"2025-11-17","source":"AABB 2025-11-17"},{"claim":"台灣健保 Zolgensma 每劑價格","value":4900,"unit":"萬新台幣","as_of":"2023-06-24","source":"ETtoday 2023-06-24"},{"claim":"台灣預估每年符合給付嬰兒","value":8,"unit":"人","as_of":"2023-06-24","source":"ETtoday 2023-06-24"},{"claim":"中山醫個案給藥日齡","value":57,"unit":"天","as_of":"2024-06-08","source":"TVBS 2024-06-08"},{"claim":"台灣 SMA 病人數","value":400,"unit":"人","as_of":"2024-06-08","source":"TVBS 2024-06-08"},{"claim":"SMA 年度用藥支出預估","value":38,"unit":"億新台幣","as_of":"2024-03-07","source":"公視新聞網 2024-03-07"}],"sections":["01｜The \"non-integrating\" promise behind AAV just met patient evidence","02｜The infant market holds, because the comparator is time","03｜Itvisma is the growth engine, and it sits where the risk bites hardest","04｜How the business changes: one-time pricing now carries a lifetime of monitoring","05｜Taiwan: about eight infants a year, plus a monitoring bill","06｜What would prove this call wrong","References"],"references":[{"title":"Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma","source":"BioSpace","date":"2026-11-05","url":"https://www.biospace.com/drug-development/novartis-confirms-9-reported-cases-of-tumors-in-patients-treated-with-zolgensma"},{"title":"Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy","source":"STAT","date":"2026-11-05","url":"https://www.statnews.com/pharmalot/2026/11/05/novartis-sma-zolgensma-tumor-case-reports/"},{"title":"Novartis confirms 2 tumor cases appear tied to SMA gene therapy","source":"SMA News Today","date":"2026-11-06","url":"https://smanewstoday.com/news/novartis-confirms-2-tumor-cases-appear-tied-sma-gene-therapy/"},{"title":"Novartis reports cases of tumours in children following treatment with Zolgensma","source":"swissinfo.ch (Keystone-SDA","date":"2026-11-06","url":"https://www.swissinfo.ch/eng/pharma-health/novartis-reports-cases-of-tumours-in-children-following-treatment-with-zolgensma/92340287"},{"title":"FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy","source":"Newsroom America","date":"2026-11-06","url":"https://newsroomamerica.com/a/O32KlbFgO3X4OF1TzvGJhs0T3Cg/fda_says_postmarketing_reports_link_zolgensma_to_malignancies_including_confirmed_insertional_oncogenesis_involving_the_gli1_gene_and_warns_the_risk_applies_to_itvisma_as_well.html"},{"title":"Novartis Says Tumors Found in Children Given SMA Gene Therapy","source":"Bloomberg","date":"2026-11-06","url":"https://bloomberg.com/news/articles/2026-11-06/novartis-says-tumors-found-in-children-given-sma-gene-therapy"},{"title":"Novartis Third Quarter and Nine Months 2026 Condensed Interim Financial Report","source":"Novartis","date":"2026-10-27","url":"https://www.novartis.com/sites/novartis_com/files/q3-2026-interim-financial-report-en.pdf"},{"title":"FDA approves new intrathecal administration route for SMA gene therapy (Itvisma","source":"NeurologyLive","date":"2025-11-24","url":"https://www.neurologylive.com/view/fda-approves-new-intrathecal-administration-route-spinal-muscular-atrophy-gene-therapy"},{"title":"FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy","source":"US FDA","date":"2019-05-24","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy"},{"title":"FDA restricts use of bluebird's Skysona gene therapy","source":"pharmaphorum","date":"2025-08-11","url":"https://pharmaphorum.com/news/fda-restricts-use-bluebirds-skysona-gene-therapy"},{"title":"FDA Adds Boxed Warning for Sarepta's DMD Gene Therapy","source":"AABB","date":"2025-11-17","url":"https://www.aabb.org/news-resources/news/article/2025/11/17/fda-adds-boxed-warning-for-sarepta-s-dmd-gene-therapy"},{"title":"天價罕病藥8月起納健保！SMA基因治療一劑4900萬","source":"ETtoday","date":"2023-06-24","url":"https://www.ettoday.net/news/20230624/2526352.htm"},{"title":"新生兒患罕病！健保給付1劑4900萬針劑 成功治療最年輕患者","source":"TVBS","date":"2024-06-08","url":"https://news.tvbs.com.tw/health/2511617"},{"title":"罕病律師陳俊翰遺願成真 脊髓性肌萎症藥物給付放寬","source":"PTS News","date":"2024-03-07","url":"https://news.pts.org.tw/article/684366"}],"images":[{"alt":"Fig. 1｜Breaking down nine tumor reports","url":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients-en/figure-01.png"},{"alt":"Fig. 2｜How the AAV vector landed near GLI1","url":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients-en/figure-02.png"},{"alt":"Fig. 3｜Zolgensma group Q3 2026 sales","url":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients-en/figure-03.png"},{"alt":"Fig. 4｜How the FDA handled three gene therapy safety events","url":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-11）。Zolgensma tumors put Novartis's older-patient SMA growth at risk。https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “The infant product stays with added monitoring, while Itvisma's older-patient market gets repriced”?","a":"The infant product stays with added monitoring, while Itvisma's older-patient market gets repriced."},{"q":"What are the key developments in “Novartis confirmed nine tumor reports on November 5, two with vector DNA integrated near GLI1”?","a":"Novartis confirmed nine tumor reports on November 5, two with vector DNA integrated near GLI1."},{"q":"What are the key developments in “Zolgensma group sales rose 34% to $404 million in Q3 2026, with US growth driven by Itvisma”?","a":"Zolgensma group sales rose 34% to $404 million in Q3 2026, with US growth driven by Itvisma."}]}